Development Stage Preclinical
Preclinical
Phase I
Phase II
Phase III
Approved
Preclinical: Animal & In-vitro studies
MOTS-c
Last updated: 1/22/2026 Last reviewed: 1/22/2026
At a Glance
MOTS-c is a mitochondria-derived peptide studied for potential roles in metabolism and cellular stress responses.
⚠️ Preclinical evidence: Much of the evidence base is from animal/in vitro work. This page summarizes research only and does not provide medical advice or dosing recommendations.
Evidence Summary
Low Confidence Animal Study >10 YearsA widely cited preclinical study reported metabolic effects of MOTS-c in models of obesity and insulin resistance. [PMID: 25738459]
Safety & Unknowns (High Level)
- Human efficacy and long-term safety are not established by preclinical studies.
Key Studies
| Year | Type | Topic | Citation |
|---|---|---|---|
| 2015 | Preclinical | Metabolic homeostasis and obesity/insulin resistance models | [PMID: 25738459] |
📚 See linked items in the Literature section.